Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/24/2026 | $7.00 | Buy | Guggenheim |
| 11/7/2025 | $3.00 | Buy | Roth Capital |
| 9/29/2025 | $13.00 | Buy | Chardan Capital Markets |
| 3/25/2025 | Outperform | William Blair | |
| 11/25/2024 | $10.00 | Buy | H.C. Wainwright |
| 9/9/2024 | $5.00 | Outperform | Leerink Partners |
| 8/27/2024 | $6.00 | Buy | B. Riley Securities |
| 10/21/2022 | $5.00 | Outperform → Mkt Perform | SVB Leerink |
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2026, informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.According to the Notice, Immunic has regained compliance with the minimum bid price requirement, because the closing bid price of the Company's common stock was at $1.00 pe
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –– Served on Original Team Responsible for the Launch of Copaxone® in the United States –NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.Mr. Congleton has a strong track record of building and leadin
– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –– Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Acid –– Multi-Layered Intellectual Property Strategy Expected to Provide Protection at Least Into 2041 in the United States and Into 2039 in Europe –NEW YORK, March 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European Patent Office (EPO) has granted a key European patent, EP3713554, directed to l
Guggenheim initiated coverage of Immunic with a rating of Buy and set a new price target of $7.00
Roth Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $3.00
Chardan Capital Markets initiated coverage of Immunic with a rating of Buy and set a new price target of $13.00
3 - IMMUNIC, INC. (0001280776) (Issuer)
3 - IMMUNIC, INC. (0001280776) (Issuer)
3 - IMMUNIC, INC. (0001280776) (Issuer)
4/A - IMMUNIC, INC. (0001280776) (Issuer)
4/A - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
D - IMMUNIC, INC. (0001280776) (Filer)
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –– Served on Original Team Responsible for the Launch of Copaxone® in the United States –NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.Mr. Congleton has a strong track record of building and leadin
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr
– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)